ERBB2 and breast cancer: For example, while 90% of breast cancer diagnosis are early-stage (63), approximately 1 in 6 women with node-positive HR+/HER2- early-stage BC receiving endocrine therapy will experience recurrence or death within 5-years of initiating treatment (64).